Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST)
What is the goal of the study?
Multicenter, block-randomized, double-masked, placebo-controlled trial to compare the safety and efficacy of stopping adalimumab treatment versus continuing adalimumab treatment in patients with uveitis associated with juvenile idiopathic arthritis (JIA). The primary objective is to compare time to recurrence of ocular inflammation between JIA-associated uveitis patients randomized to stop adalimumab treatment and patients randomized to continue treatment.
Who can participate in the study?
Please contact the study team listed below to learn more.